INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Nov 10, 2022 | Press Releases

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Nov. 10, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

Nov 1, 2022 | Press Releases

– The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. – The INVOcell...

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

Oct 21, 2022 | Press Releases

SARASOTA, Fla., Oct. 21, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture (“IVC”)...

INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

Oct 17, 2022 | Press Releases

SARASOTA, Fla. and ANAHEIM, Calif., Oct. 17, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment...

Dr. Sue Ellen Carpenter of INVO Bioscience’s Atlanta-based INVO Center – Bloom Fertility – Named Top Doctor by Castle Connolly

Sep 22, 2022 | Press Releases

SARASOTA, Fla. and ATLANTA, Sept. 22, 2022 — INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture...